OncoGinecologia.net
Ematologia.net
Gastroenterologia.net
Reumatologia

DrugsNews.net

Drugs Xagena

FDA has approved Lutathera, a new treatment for gastroenteropancreatic neuroendocrine tumors


The FDA ( U.S. Food and Drug Administration ) has approved Lutathera ( Lutetium Lu 177 dotatate ) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors ( GEP-NETs ).
This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs.
Lutathera is indicated for adult patients with somatostatin receptor-positive GEP-NETs.

GEP-NETs are a rare group of cancers with limited treatment options after initial therapy fails to keep the cancer from growing.

GEP-NETs can be present in the pancreas and in different parts of the gastrointestinal tract such as the stomach, intestines, colon and rectum. It is estimated that approximately one out of 27,000 people are diagnosed with GEP-NETs per year.

Lutathera is a radioactive drug that works by binding to a part of a cell called a somatostatin receptor, which may be present on certain tumors. After binding to the receptor, the drug enters the cell allowing radiation to cause damage to the tumor cells.

The approval of Lutathera was supported by two studies.

The first was a randomized clinical trial in 229 patients with a certain type of advanced somatostatin receptor-positive GEP-NET. Patients in the trial either received Lutathera in combination with the drug Octreotide or Octreotide alone. The study measured the length of time the tumors did not grow after treatment ( progression-free survival ). Progression-free survival was longer for patients taking Lutathera with octreotide compared to patients who received octreotide alone. This means the risk of tumor growth or patient death was lower for patients who received Lutathera with Octreotide compared to that of patients who received only Octreotide.

The second study was based on data from 1,214 patients with somatostatin receptor-positive tumors, including GEP-NETS, who received Lutathera at a single site in the Netherlands. Complete or partial tumor shrinkage was reported in 16% of a subset of 360 patients with GEP-NETs who were evaluated for response by the FDA. Patients initially enrolled in the study received Lutathera as part of an expanded access program. Expanded access is a way for patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs for treatment use.

Common side effects of Lutathera include low levels of white blood cells ( lymphopenia ), high levels of enzymes in certain organs ( increased GGT, AST and/or ALT ), vomiting, nausea, hyperglycemia and hypokalemia.

Serious side effects of Lutathera include low levels of blood cells ( myelosuppression ), development of certain blood or bone marrow cancers ( secondary myelodysplastic syndrome and leukemia ), kidney damage ( renal toxicity ), liver damage ( hepatotoxicity ), abnormal levels of hormones in the body ( neuroendocrine hormonal crises ) and infertility.
Lutathera can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception.
Patients taking Lutathera are exposed to radiation. Exposure of other patients, medical personnel, and household members should be limited in accordance with radiation safety practices. ( Xagena )

Source: FDA, 2018

XagenaMedicine_2018



Indietro